PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017

Wirtschaftsnachrichten (Symbolbild). pixabay.com

PR Newswire

SEATTLE, Feb. 8, 2017

SEATTLE, Feb. 8, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster presentation for its lead product candidate, PRX-OTC, at the 13th Annual WORLDSymposium™ 2017, to be held at the Manchester Grand Hyatt, February 13-17, 2017 in San Diego. PRX-OTC is in development for the treatment of ornithine transcarbamylase deficiency.

Title of Poster: mRNA Delivery to the Liver Corrects Ornithine Transcarbamylase Deficiency in a Mouse Disease Model
Presenter: Gordon Brandt, M.D.
Time: Tuesday, February 14 from 4:30-6:30 p.m. PST

About PhaseRx

PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.

Contacts:

Company Contact:
Erin Cox
PhaseRx, Inc.
Director of Investor Relations
erin@phaserx.com
206.805.6306

Corporate Communications Contact:
Jason Spark
Canale Communications
Senior Vice President
jason@canalecomm.com
619-849-6005

ARIVA.DE Börsen-Geflüster

Kurse

PhaseRx

0,00%

Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
robert.uhl@westwicke.com
858.356.5932

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-to-present-data-for-prx-otc-at-the-13th-annual-worldsymposium-2017-300403968.html

SOURCE PhaseRx, Inc.

Mehr Nachrichten zur PhaseRx Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.